Back to Search Start Over

Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis.

Authors :
Steinberg J
Hughes S
Hui H
Allsop MJ
Egger S
David M
Caruana M
Coxeter P
Carle C
Onyeka T
Rewais I
Monroy Iglesias MJ
Vives N
Wei F
Abila DB
Carreras G
Santero M
O'Dowd EL
Lui G
Tolani MA
Mullooly M
Lee SF
Landy R
Hanley SJB
Binefa G
McShane CM
Gizaw M
Selvamuthu P
Boukheris H
Nakaganda A
Ergin I
Moraes FY
Timilshina N
Kumar A
Vale DB
Molina-Barceló A
Force LM
Campbell DJ
Wang Y
Wan F
Baker AL
Singh R
Salam RA
Yuill S
Shah R
Lansdorp-Vogelaar I
Yusuf A
Aggarwal A
Murillo R
Torode JS
Kliewer EV
Bray F
Chan KKW
Peacock S
Hanna TP
Ginsburg O
Van Hemelrijck M
Sullivan R
Roitberg F
Ilbawi AM
Soerjomataram I
Canfell K
Source :
International journal of cancer [Int J Cancer] 2024 Apr 15; Vol. 154 (8), pp. 1394-1412. Date of Electronic Publication: 2023 Dec 11.
Publication Year :
2024

Abstract

While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36-1.61, I <superscript>2</superscript>  = 0; people with COVID-19: aOR = 1.58, 95% CI: 1.41-1.77, I <superscript>2</superscript>  = 0.58; inpatients with COVID-19: aOR = 1.66, 95% CI: 1.34-2.06, I <superscript>2</superscript>  = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68-2.68, I <superscript>2</superscript>  = 0.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37-1.75) at 1 year and aOR = 0.98 (95% CI: 0.80-1.20) at 5 years post-cancer diagnosis/treatment. In conclusion, before COVID-19-vaccination, risk of COVID-19-related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment.<br /> (© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)

Details

Language :
English
ISSN :
1097-0215
Volume :
154
Issue :
8
Database :
MEDLINE
Journal :
International journal of cancer
Publication Type :
Academic Journal
Accession number :
38083979
Full Text :
https://doi.org/10.1002/ijc.34798